Nicholas Brennan1, Mohammad H Dehabadi2, Sandhya Nair3, Ana Quartilho4, Catey Bunce4, Ian Reekie3, Raal Obikpo3. 1. Moorfields Eye Hospital NHS Foundation Trust, London EC1V 2PD, UK. 2. London North West Healthcare NHS Trust, London HA1 3UJ, UK. 3. North Middlesex University Hospital NHS Trust, London N18 1QX, UK. 4. NIHR Biomedical Research Centre, Moorfields Eye Hospital NHS Foundation Trust and UCL Institute of Ophthalmology, London EC1V 2PD, UK.
Abstract
AIM: To establish the efficacy and safety of bimatoprost 0.03% monotherapy in glaucoma and ocular hypertension (OHT) patients with inadequate intraocular pressure (IOP)on current therapy. METHODS: Pre- and post-switch IOPs were analyzed for 59 consecutive patients who were switched from current therapy to bimatoprost monotherapy between 2011-2015. Demographic information, diagnosis, and any adverse events were recorded. Change in IOP post-pre switch was analyzed using a 2-sided Student's paired t-test at the 5% significance level. RESULTS: There was a statistically significant mean reduction in IOP at the first follow up visit, which was maintained at subsequent follow up visits for patients regardless of diagnosis, or pre-switch treatment (P<0.001). Subgroup analysis also demonstrated a statistically significant mean reduction in IOP when looking at OHT patients only, as well as patients with any diagnosis switched from latanoprost monotherapy to bimatoprost monotherapy (P<0.001). CONCLUSION: This is the largest independent data set which supports switching glaucoma patients with poor response to current treatment onto bimatoprost monotherapy before considering other adjuvant medical or more invasive therapy.
AIM: To establish the efficacy and safety of bimatoprost 0.03% monotherapy in glaucoma and ocular hypertension (OHT) patients with inadequate intraocular pressure (IOP)on current therapy. METHODS: Pre- and post-switch IOPs were analyzed for 59 consecutive patients who were switched from current therapy to bimatoprost monotherapy between 2011-2015. Demographic information, diagnosis, and any adverse events were recorded. Change in IOP post-pre switch was analyzed using a 2-sided Student's paired t-test at the 5% significance level. RESULTS: There was a statistically significant mean reduction in IOP at the first follow up visit, which was maintained at subsequent follow up visits for patients regardless of diagnosis, or pre-switch treatment (P<0.001). Subgroup analysis also demonstrated a statistically significant mean reduction in IOP when looking at OHT patients only, as well as patients with any diagnosis switched from latanoprost monotherapy to bimatoprost monotherapy (P<0.001). CONCLUSION: This is the largest independent data set which supports switching glaucomapatients with poor response to current treatment onto bimatoprost monotherapy before considering other adjuvant medical or more invasive therapy.
Authors: Robert J Casson; Lance Liu; Stuart L Graham; William H Morgan; John R Grigg; Anna Galanopoulos; Andrew Crawford; Philip H House Journal: J Glaucoma Date: 2009 Oct-Nov Impact factor: 2.503
Authors: Yih-Chung Tham; Xiang Li; Tien Y Wong; Harry A Quigley; Tin Aung; Ching-Yu Cheng Journal: Ophthalmology Date: 2014-06-26 Impact factor: 12.079
Authors: Stefan Pfennigsdorf; Osman Ramez; Gerrit von Kistowski; Birgit Mäder; Peter Eschstruth; Michael Froböse; Ulrich Thelen; Christoph Spraul; Dietmar Schnober; Hazel Cooper; Thomas Laube Journal: Clin Ophthalmol Date: 2012-05-11
Authors: Xiaohong Li; Fen He; B'Ann T Gabelt; Yun Wang; Suping Cai; Juanhui Cao; Ning Fan; Paul L Kaufman; Xuyang Liu Journal: PLoS One Date: 2016-03-24 Impact factor: 3.240